125 related articles for article (PubMed ID: 37706660)
1. Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2
Wei Q; Yao K; Yang J; Zhou Q; Liu P; Chen J; Liu H; Lai Y; Cao P
J Med Chem; 2023 Sep; 66(18):12894-12910. PubMed ID: 37706660
[TBL] [Abstract][Full Text] [Related]
2. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
[TBL] [Abstract][Full Text] [Related]
3. IDH2/R140Q mutation confers cytokine-independent proliferation of TF-1 cells by activating constitutive STAT3/5 phosphorylation.
Yang J; Chen J; Chang J; Sun X; Wei Q; Cai X; Cao P
Cell Commun Signal; 2024 Feb; 22(1):116. PubMed ID: 38347540
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
[TBL] [Abstract][Full Text] [Related]
5. Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.
Chen J; Yang J; Sun X; Wang Z; Cheng X; Lu W; Cai X; Hu C; Shen X; Cao P
Sci Rep; 2017 Nov; 7(1):16458. PubMed ID: 29184081
[TBL] [Abstract][Full Text] [Related]
6. Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
Huang R; Liao X; Li J; Wei J; Su X; Lai X; Liu B; Zhu F; Huang Y; Li Q
Oncol Rep; 2019 May; 41(5):2876-2888. PubMed ID: 30896832
[TBL] [Abstract][Full Text] [Related]
7. Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations.
Tawfik HO; Mousa MHA; Zaky MY; El-Dessouki AM; Sharaky M; Abdullah O; El-Hamamsy MH; Al-Karmalawy AA
Bioorg Chem; 2024 Aug; 149():107483. PubMed ID: 38805913
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel 2-arylbenzimidazoles as selective mutant isocitrate dehydrogenase 2 R140Q inhibitors.
Li Z; Wu X; Jia L; Li J; Zhang R; Tang H; Li Z; Bu H; Shen C
Bioorg Med Chem Lett; 2020 May; 30(9):127070. PubMed ID: 32143887
[TBL] [Abstract][Full Text] [Related]
9. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
[TBL] [Abstract][Full Text] [Related]
10. Identification of new IDH2
Chen X; Wu X; Gao J; Ying H; Dong X; Che J; Shen Z
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000063. PubMed ID: 33184958
[TBL] [Abstract][Full Text] [Related]
11. Transgenic IDH2
Wang D; Zheng L; Cheng BYL; Sin CF; Li R; Tsui SP; Yi X; Ma ACH; He BL; Leung AYH; Sun X
Oncogene; 2023 Apr; 42(16):1272-1281. PubMed ID: 36739363
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Ma R; Yun CH
Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
[TBL] [Abstract][Full Text] [Related]
13. [Effects of IDH2 Gene Mutation on Clinical Characteristics and Prognostic of Patients with Acute Myeloid Leukemia].
Luo LQ; Peng ZY; Liu X; Yu WZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1077-1082. PubMed ID: 31418360
[TBL] [Abstract][Full Text] [Related]
14. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
Che J; Huang F; Zhang M; Xu G; Qu B; Gao J; Chen B; Zhang J; Ying H; Hu Y; Hu X; Zhou Y; Gao A; Li J; Dong X
Eur J Med Chem; 2020 Oct; 203():112491. PubMed ID: 32679449
[TBL] [Abstract][Full Text] [Related]
16. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
17. Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia.
Ashraf S; Noguera NI; Di Giandomenico J; Zaza S; Hasan SK; Lo-Coco F
Ann Hematol; 2013 Oct; 92(10):1319-23. PubMed ID: 23949315
[TBL] [Abstract][Full Text] [Related]
18. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies.
Kranendijk M; Salomons GS; Gibson KM; Van Schaftingen E; Jakobs C; Struys EA
Biochim Biophys Acta; 2011 Nov; 1812(11):1380-4. PubMed ID: 21889589
[TBL] [Abstract][Full Text] [Related]
19. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
[TBL] [Abstract][Full Text] [Related]
20. An integrative computational approach for the identification of dual inhibitors of isocitrate dehydrogenase 1 and 2 from phytocompounds of
Bello RO; Okunlola ST; Kumar N; Victor O; Jimoh TO; Abdulsalam ZN; Kehinde IO; Umar HI
J Biomol Struct Dyn; 2023 Aug; ():1-17. PubMed ID: 37559488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
